Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials.

Poon M, Zhang L, Mok F, Li K, Emmenegger U, Wong E, Zhou M, Lam H, Lao N, Chow E.

J Comp Eff Res. 2013 Jan;2(1):77-91. doi: 10.2217/cer.12.72. Review.

PMID:
24236524
2.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
3.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
4.
5.

[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].

Dong M, Feng FY, Zhang Y, Xie GR, Wang YJ, Liu JW, Song ST, Zhou QH, Ren J, Jiao SC, Li J, Wang XW, Chen Q, Wang ZH, Xu N, Feng JF.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):215-20. Chinese.

PMID:
18756940
6.

Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates.

Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.

Ann Pharmacother. 2011 Oct;45(10):1199-206. doi: 10.1345/aph.1Q239. Epub 2011 Sep 27.

7.

Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.

Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay JW.

Gen Dent. 2010 Nov-Dec;58(6):484-92; quiz 493-4.

PMID:
21062718
8.

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.

Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL.

Breast Cancer Res Treat. 2009 Aug;116(3):433-9. doi: 10.1007/s10549-009-0432-z. Epub 2009 Jun 12.

PMID:
19521766
9.

Bisphosphonate-related osteonecrosis of the jaw in randomized clinical trials.

Kyrgidis A.

Breast Cancer Res Treat. 2010 Jan;119(1):253-4. doi: 10.1007/s10549-009-0466-2. Epub 2009 Jul 8. No abstract available.

PMID:
19585235
10.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632
11.

The use of bisphosphonates in cancer patients.

Wu S, Dahut WL, Gulley JL.

Acta Oncol. 2007;46(5):581-91. Review.

PMID:
17562434
12.

Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.

Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, Bedard G, Lao N, Chow R, Chow E.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):435-44. doi: 10.1016/j.clon.2013.03.003. Epub 2013 Apr 10. Review.

PMID:
23582277
13.

All bisphosphonates are (or may not be) the same: potential reasons for clinical differences.

Miller PD.

J Womens Health (Larchmt). 2010 Apr;19(4):665-9. doi: 10.1089/jwh.2010.1945. No abstract available.

PMID:
20415640
14.

Denosumab an option for patients with bone metastasis from breast cancer.

Barton MK.

CA Cancer J Clin. 2011 May-Jun;61(3):135-6. doi: 10.3322/caac.20116. Epub 2011 May 1. No abstract available.

15.

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.

Grant BT, Amenedo C, Freeman K, Kraut RA.

J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019.

PMID:
18201600
16.

Adverse effects of bisphosphonates.

Abrahamsen B.

Calcif Tissue Int. 2010 Jun;86(6):421-35. doi: 10.1007/s00223-010-9364-1. Epub 2010 Apr 21. Review.

PMID:
20407762
17.

Denosumab and the current status of bone-modifying drugs in breast cancer.

Lee BL, Higgins MJ, Goss PE.

Acta Oncol. 2012 Feb;51(2):157-67. doi: 10.3109/0284186X.2011.633555. Epub 2011 Dec 12. Review.

PMID:
22150116
18.

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.

Monegal A, Guañabens N, Suárez MJ, Suárez F, Clemente G, García-González M, De la Mata M, Serrano T, Casafont F, Tome S, Barrios C, Navasa M.

Transpl Int. 2009 Feb;22(2):198-206. doi: 10.1111/j.1432-2277.2008.00763.x. Epub 2008 Sep 15. Erratum in: Transpl Int. 2009 Jun;22(6):679. Torne, Santiago [corrected to Tome, Santiago].

19.

Bisphosphonates and breast carcinoma.

Lipton A.

Cancer. 1997 Oct 15;80(8 Suppl):1668-73. Review.

PMID:
9362434
20.

Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.

Voss PJ, Joshi Oshero J, Kovalova-Müller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, Lemound J, Metzger MC, Schmelzeisen R.

J Craniomaxillofac Surg. 2012 Dec;40(8):719-25. doi: 10.1016/j.jcms.2012.01.005. Epub 2012 Feb 14.

PMID:
22336489

Supplemental Content

Support Center